Pharmaceutical manufacturers desirous of marketing systemically administered steroidal or non-steroidal contraceptives in the U.S. must, at present, perform not only routine chronic toxicity studies, but must make a commitment to study these drugs for seven years in beagles and ten years in monkeys. This is a requirement of the Food and Drug Administration (FDA). Although the purpose of these long-range studies is to ascertain the effect of the drugs on all major organs and certain hematologic and biochemical parameters, the prime area of interest has become the mammary glands.
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The requirement for the long-term studies was initiated in 1967 following the report of mammary nodule induction in dogs and monkeys by the progestagen, ethynerone, which was being investigated as a contraceptive agent by Merck, Sharp and Dohme.
Study Design
The potential use of systemically administered contraceptives for almost half of a lifetime of the human female obviously called for a study design of greater duration than heretofore required for any drug. Much debate ensued among the FDA and its consultants concerning the appropriate animal species, the dosage and the frequency of drug administration.
The beagle and the rhesus monkey were chosen because of the ready availability of these animals.
It was decided that dosages in the beagle would be 1 or 2 times, 10 times and 25 times the human dose on a mg./kg. basis for 7 years. I n the monkey dosages were 1 or 2 ti mes, 10 times and 50 times the human dose on a mg./kg. basis for 10 years. Drug firms marketing or investigating more than one ratio of the same progestagen to the same estrogen were permitted to choose the most popular ratio.
The drugs were administered to the animals by the same route and on the same schedule as in humans.
Results
Although these studies have been conducted for a period over 5 years in some cases, the monkeys have deomonstrated only a very occasional mammary nodule or local mammary hyperplasia so that the ensuing discussion w:ll be confined to the beagle data.
The following eight slides (Fig. 1 ) depict the results of various compounds under study. It should be noted that some beagle nodules in control and treated animals come and go during the year so that the cut off dates at the end of each year are not necessarily indicative of the picture that occurred in preceding or succeeding months.
Among the marketed oral contraceptives, those involved in a cyclic regimen, i.e., Ovral, Ortho Novum 1/80, Norlestrin, Enovid-E, Ovulen and Demulen appear to have no major findings, although the high dose Norlestrin at the end of the fourth and fifth years is slightly suspicious.
The one remaining marketed sequential, Oracon, has induced nodules in the nipples of number of dogs which appear to be sebaceous cysts. There are, however, a few nodules in the mammary tissue.
The one marketed progestagen given continuously, viz., norethindrone, and the investigational continuous progestagen, norgestrel, have shown an absence of tumorigenic potential to date.
Two formerly investigational continuously administered progestagens, chlormadinone acetate and megestrol acetate, were highly tumorigenic in the beagle, beginning in the second and third year, respectively, of drug administration. Biopsies of several nodules from the mid and high dose chlormadinone dogs revealed some benign tumors and some malignant tumors, a few with evidence of invasiveness. Chlormadinone acetate was withdrawn from the dogs at the end of three years and some nodules in the mid and high dose dogs regressed partially or completely, although new ones continued to appear, at least during the first six months after withdrawal. Biopsies were also performed on several megestrol acetate dogs and those isolated specimens were benign. Four dogs per group have been withdrawn from megestrol acetate treatment and are being observed for nodule regression. C-Quens, a formerly marketed sequential containing chlormadinone acetate, also produced nodules in dogs but perhaps because the chlormadinone was given only five days per month instead of continuously, the nodules appeared in large numbers a year later than those in the continuous regimen. All C-Quens dogs have been removed from drug and are being observed.
Medroxyprogesterone acetate, administered intramuscularly in a regimen of an injection every three months, is highly tumorigenic in the beagle, with malignant nodules and metastases in the high dose dogs.
Part IV of Figure I demonstrates the results of studies being conducted by FDA. Ethynerone, the progestagen that resulted in the uniform requirement for longterm dog and monkey studies for contraceptive drugs, has been confirmed in the FDA study as being exceedingly tumorigenic. Likewise, chloroethynyl norgestrel, a compound closely related to ethynerone but never studied in man, has been found to be tumorigenic in the FDA study. Anagestone acetate, another 14 FIGURE 1 NUMBER OF DOGS WITH NODULES AND NUMBER OF NODULES AT END OF YEAR investigational drug formerly in human trials, is also tumorigenic with evidence of mestastases.
Interestingly, the estrogens, mestranol and ethinyl estradiol, have produced no nodules in dogs. 
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Discussion
At present it is reasonable to conclude, with respect to the beagle, that the contraceptives which contain testosterone derivatives as their progestagen component, such as norethindrone and norgestrel, are less prone to become tumor inducers with protracted administration than are the progesterone analogues such as chlormadinone and medroxyprogesterone.
However, this freedom from tumorigenic potential of the androgenic progestagens can be obliterated by certain chemical changes of the parent compound, as evidenced by the cases of ethynerone and chloroethynyl norgestrel. The tumorigenicity of the progesterone analogues was a surprise since carcinogenicity in the dog has heretofore been attributed to estrogens. As noted in the FDA studies, the estrogens have been nontumorigenic.
The progesterone analogues, with the exception of megestrol and ethynerone, also caused a high incidence of pyometra and death in mid and particularly high dose dogs, requiring hysterectomies in the remaining dogs in order to continue the experiments.
Following the appearance of tumors in the beagles treated with progesterone analogues, many questions were raised about the suitability for contraceptive studies of the canine, which is anestrus for most of the year except for brief semiannual heat periods. Further, questions arose about the similarity, or lack thereof, of the metabolic patterns of the various steroids in dogs and man. At the time that the protocols were developed, the FDA and its consultants felt that the studies should simulate the usual toxicologic studies in animals. There were little or no data on metabolism of the various compounds in the beagle and the monkey. Such data are beginning to emerge. For example, Figure 2 gives the comparison of plasma levels in dogs, monkeys and humans administered medroxyprogesterone acetate intramuscularly.
With this particular drug there is a close similarity in rate of absorption and subsequent plasma level fall off in all three species. However, these measurements were performed utilizing a radioimmunoassay technique which fails to differentiate between parent compound and metabolites with &dquo;medroxyprogesterone-like&dquo; activity. There is some evidence from subsequent studies that metabolism is somewhat different in the dog than in the human but additional studies are needed to clarify this, 1, 2 Another doubt which was voiced concerning the appropriateness of the beagle related to what was described as the well-known incidence of spontaneous mammary tumors in this species. Andeisen reported a 54% incidence of clinically evident mammary tumors in the female beagle by 6 to 8 years of age, and a 27% mortality rate from mammary carcinoma over a 13 year period.3 In the studies conducted by FDA and the manufacturers of oral contraceptives, spontaneous incidence of mammary tumors in the control animals is much lower, averaging about 12% between 5 and 6 years; it should also be noted that these are very carefully performed studies with skilled technicians able to palpate and thus tabulate nodules 1 to 2 mm. in diameter. Interestingly, the cyclic regimens under study in the dog, regimens which were criticized as being inappropriate to the estrus and anestrus patterns in the dog, have produced no harmful effects in this species, although it is likely that this is due to the fact that only the testosterone derivatives and not the progesterone derivatives were tested in this manner. As further evidence for this, when chlormadinone was given in a sequential regimen involving only 5 days per month of this drug, it produced tumors in about as large a number as continuous administration of chlormadinone.
The critics of the use of the dog have not questioned the use of the monkey in whom mammary carcinoma is indeed a rare event. The human female falls between the dog and the monkey in spontaneous incidence of mammary tumors and perhaps it was a very wise decision to choose the dog and monkey. It appears that the progesterone analogues in the beagle are accelerating and magnifying a spontaneous pathologic phenomenon whereas the testosterone derivatives have been negative so far. Time will tell whether the latter also have some influence on the beagle. The monkey to date is resistant to both types of compounds but a word of caution is needed here: 1 to 2 year studies of ethynerone in the monkey revealed atypical hyperplasia interpreted by some pathologists as malignant changes; these were noted only upon careful histopathologic examination of what appeared clinically to be slight mammary hyperplasia.
Finally, it should be noted that the progesterone analogues produce a stimulatory action on the mammary gland of the dog and the humanmedroxy-progesterone given postpartum to human females does not suppress lactationwhereas the testosterone analogues induce an exhaustion phenomenon in the mammary elements of both species. If one can expalin the tumorigenic and carcinogenic potential of the progesterone analogues in the dog by their stimulatory effect on the mammary gland, then perhaps the dog may not be as useless as some would have us believe for predicting the potential of thses compounds to induce tumors in the human.
Following the obsservance of the large number of mammary nodules in the beagle, C-Quens was removed from the market. Provest, a combination of medroxyprogesterone acetate and ethinyl estradiol, was also removed. Investigational studies on chlormadinone acetate, megestrol acetate, ethynerone and anagestrone acetate were also terminated. The lack of advantages of these compounds over the &dquo;clean&dquo; compounds administered cyclically, sequentially or continuously, rendered these regulatory actions mandatory. However, medroxyprogesterone acetate administered intramuscularly every 3 months is such a unique method and has applicability to to a certain small patient population, that limited clinical trials with informed patient consent, have been permitted.
Summary
Data have been presented on long-term administration of various progestational and estrogen compounds in the beagle for the purpose of determining which compounds are tumorigenic in this species. It was observed that among the progestational compounds the progesterone derivatives appear to predominate in tumorigenic effect, whereas the testosterone derivatives are innocuous to date. The estrogens have also been devoid of tumorigenic activity.
Dogs with malignant nodules also harbor benign nodules, with the latter often appearing subsequent to the occurrence of malignant nodules. The extrapolation of these findings to the human, is, of course, unknown; many years and hundred of thousands of human females followed in epidemiologic studies will be necessary to answer that question. To date the monkey studies have been negative, with the possible exception of ethynerone. Should positive findings appear in the monkey, a species highly resistant to mammary carcinoma, a reassessment of the safety of steroidal contraceptives will be required.
I. INTRODUCTION
There is mounting evidence that human cancer has its genesis in the environment (1) . Based on the contention that environmental carcinogens are the causation of cancer, various authorities claim that such environmentally-derived cancers may be of the order of 60 to 90 percent.
